CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...
Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback